Option chain shows key data for Anteris Technologies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Anteris Technologies.

Anteris Technologies (NASDAQ:AVR) Stock, Option Chain

Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.

Anteris Structural Heart PMS White

Equities

News

Markets

Movers

General

Barclays analyst initiates Positive coverage on Anteris Technologies, forecasting a 4%-5% U.S. TAVR market share for DurAVR by 2030.





Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst

Coca-Cola: A Reliable Dividend Stock

Initiation

Pre-Market Outlook

Analyst Ratings

Trading Ideas

ASND

ICLR

This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Events

EDWARDS INTUITY Valve System Receives CE Mark

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies Global Corp.

Avantis Real Estate ETF

Averox Inc

AVARONE METALS INC ORD by Avarone Metals Inc

Avarone Metals Inc

AVENIR WELLNESS SOLUTION by Avenir Wellness Solutions Inc.

Avenir Wellness Solutions Inc

WIIM

MarineMax shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) reported worse-than-expected fourth-quarter EPS and <a href="https://www.benzinga.com/news/earnings/25/01/43128325/ge-vernova-mixed-q4-revenue-misses-but-orders-surge-22-amid-strong-electrification-demand">revenue on Wednesday</a>.
The company reported revenue growth of 5% year-over-year to $10.559 billion and +9% organically, missing the consensus of $10.78 billion.
The company achieved orders totaling $13.2 billion, reflecting a 22% organic increase, ~1.3 times revenue, driven primarily by Power and Electrification equipment. Earnings per share for the quarter were $1.73, compared to $0.72 a year ago, missing the consensus of $2.55.
"GE Vernova built a strong foundation in 2024 with solid orders and revenue growth, as well as significant margin expansion and cash generation. We saw strength in Power and Electrification and improvement in Wind, while growing our equipment backlog at better margins," stated GE Vernova CEO Scott Strazik.
GE Vernova reaffirms its 2025 outlook with $36 billion – $37 billion in revenue versus a consensus of $36.88 billion, a high single-digit adjusted EBITDA margin, and $2 billion – $2.5 billion in free cash flow.
GE Vernova shares gained 2.7% to close at $427.10 on Wednesday.
These analysts made changes to their price targets on GE Vernova following earnings announcement.
<ul>
<li>JP Morgan analyst Mark Strouse maintained GE Vernova with an Overweight and raised the price target from $374 to $436.</li>
<li>Barclays analyst Julian Mitchell maintained the stock with an Overweight and raised the price target from $420 to $487.</li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-1024x489.png" alt="" class="wp-image-746761" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-1024x489.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-768x367.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

Earnings

Price Target

GE Vernova Analysts Boost Their Forecasts After Strong Q4 Results

GE Aerospace CFO Says In 2025, Do Think Spare Parts To Stay Strong

EVTL

Vertical Aerospace shares are trading lower after the company announced a $90 million public offering.

Biotech

SELLAS Life Sciences Announces Interim Analysis For Phase 3 REGAL Trial Of GPS In Acute Myeloid Leukemia Showing; Says Independent Data Monitoring Committee Recommended Trial Continue Without Modifications

COEP

Coeptis Therapeutics Holdings Expands Its Technological Initiatives To Include Cutting-Edge Artificial Intelligence And Innovative Blockchain Solutions

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $6 price target.

Reiteration

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $6 Price Target

Data corroborate previously reported preclinical data demonstrating certepetide's ability to enhance the effectiveness of immunotherapy
Preliminary results to be presented at the 2025 ASCO Gastrointestinal Cancers Symposium
BASKING RIDGE, N.J. and SUBIACO, Australia, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and WARPNINE Incorporated ("WARPNINE"), Western Australia's first not-for-profit clinical research organization for pancreatic, gastro-intestinal and rare cancers, today announced encouraging preliminary results from the Phase 1b/2a iLSTA trial (<a href="https://www.globenewswire.com/Tracker?data=viG6Z8rb5yakmCziK5MC4KHIHD449o_0_iwBwzOnKLuIVX9ogOPIlIPp1gF8kKV4bkOsW4cHmYy5OZllI3q1fdfHwQ_EiqAKt0OJn1dwseNnLMKSutHtNTo4FzoF1DPTxQwyJFbH0lXRFKDo7QySmQ==">ACTRN12623000223639</a>) evaluating certepetide (formerly LSTA1), Lisata's proprietary investigational iRGD cyclic peptide product candidate, in combination with standard-of-care (SoC) chemotherapy and immunotherapy as a first-line treatment in locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The preliminary data will be presented in a poster session, entitled, "Immunotherapy combined with a novel iRGD peptide plus nab-paclitaxel and gemcitabine for locally advanced pancreatic ductal adenocarcinoma: A prospective study," at the 2025 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on Friday, January 24, 2025 at 11:30 a.m. - 1:00 p.m. (PST) in San Franscisco, California. For a detailed summary of the poster presentation, please see the abstract available on the ASCO GI website: <a href="https://www.globenewswire.com/Tracker?data=xhbTLxEjS_qv4xxw0rdbf9Rt0I_ukgclLSLtzTm27CY4aH8IsYbd4usSpVvBiLpC4lPd65aFQ8ovirYYzJtCon_gypsrzb3eZ8Am3EwukOPCVshYZxApc7bUzgoQWUApN9BvOUHo20-Tx0AxvGFbFPmy04pHaRoIuiyMBuEeQkZuPCIJxEmyVsPtYCxVjX4u">https://meetings.asco.org/abstracts-presentations/241611</a>
The Phase 1b/2a randomized, single-blind, single-center, safety and pharmacodynamic iLSTA trial, being conducted at St John of God Subiaco Hospital in Western Australia, a leading center for clinical research and innovation, is evaluating certepetide in combination with SoC chemotherapy (nab-paclitaxel and gemcitabine) plus SoC immunotherapy (durvalumab) versus SoC alone in patients with locally advanced non-resectable PDAC. This collaboration highlights the strength of combining global expertise with local excellence to address the urgent needs of patients with pancreatic cancer. Participants in the iLSTA trial were divided into three treatment cohorts (1:1:4 ratio): Cohort 1 (n=5) received SoC chemotherapy in combination with placebo durvalumab and placebo certepetide. Cohort 2 (n=5) received SoC chemotherapy plus certepetide and placebo durvalumab. Cohort 3 (n=20) received SoC chemotherapy plus durvalumab and certepetide. The preliminary results, representing an interim analysis of the first 17 of 30 targeted patients of the iLSTA trial are as follows:
Five of 16 patients evaluable by RECIST criteria experienced a partial response after 2 cycles of treatment (4 patients were in cohort 3), with the remaining 11 patients presenting with stable disease. After 4 cycles of treatment, 9 of 16 patients demonstrated partial response (8 patients were in cohort 3). Of the remaining 7 patients, 6 demonstrated stable disease, and 1 patient (cohort 2) exhibited a complete response. Fourteen of 17 patients who completed 4 treatment cycles showed a decrease in CA19-9 levels. Six patients demonstrated &gt;90% reduction in CA19-9 (5 of whom in cohort 3), with the remaining 8 patients showing a &gt;50% reduction in CA19-9 levels (6 of whom in cohort 3). Five patients had their repeat biopsies analyzed for tumor infiltrating lymphocytes (4 of whom from cohort 3), with all patients showing significant immune cell infiltration (15% to 50% stroma infiltration). These results demonstrate the potential value of adding certepetide to the SoC regimen consisting of gemcitabine, nab-paclitaxel, and durvalumab in this patient population.

LSTA

Lisata And WARPNINE Announces Interim Phase 1b/2a Results For Certepetide In Pancreatic Cancer; 56% Show Partial Response After 4 Cycles, With Up To 90% Reduction In CA19-9 Levels; Results To Be Presented At 2025 ASCO GI Symposium

Barclays analyst Jared Shaw maintains Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) with a Overweight and raises the price target from $151 to $155.

WTFC

Barclays Maintains Overweight on Wintrust Finl, Raises Price Target to $155

Carter Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARE#NASDAQ">CARE</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.24 by 54.17 percent. This is a 1950 percent increase over losses of $(0.02) per share from the same period last year.

CARE

Carter Bankshares Q4 Adj $0.37 Beats $0.24 Estimate

BANC

Bank of California shares are trading higher after the company reported better-than-expected Q4 EPS results.

ATXS

Astria Therapeutics Initiates Phase 1a Trial Of STAR-0310 For Treatment Of Atopic Dermatitis

Cass Information Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASS#NASDAQ">CASS</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.21 by 57.14 percent. This is a 45.9 percent decrease over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $50.37 million which beat the analyst consensus estimate of $49.48 million by 1.80 percent. This is a 0.72 percent decrease over sales of $50.74 million the same period last year.

CASS

Cass Information Sys Q4 EPS $0.33 Beats $0.21 Estimate, Sales $50.37M Beat $49.48M Estimate

Heritage Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFWA#NASDAQ">HFWA</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.45 by 13.33 percent. This is a 15.91 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $57.053 million which missed the analyst consensus estimate of $60.685 million by 5.98 percent. This is a 12.48 percent increase over sales of $50.724 million the same period last year.

Earnings Beats

Earnings Misses

HFWA

Heritage Financial Q4 2024 Adj. EPS $0.51 Beats $0.45 Estimate, Sales $57.053M Miss $60.685M Estimate

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">143.00</td>
<td align="right">0.82</td>
<td align="right">0.57</td>
<td>7.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">140.99</td>
<td align="right">0.74</td>
<td align="right">0.52</td>
<td>22.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">78.45</td>
<td align="right">0.13</td>
<td align="right">0.16</td>
<td>402</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.49</td>
<td align="right">0.08</td>
<td align="right">0.15</td>
<td>56.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.11</td>
<td align="right">0.01</td>
<td align="right">0.02</td>
<td>478</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">239.73</td>
<td align="right">-1.66</td>
<td align="right">-0.69</td>
<td>12.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">98.71</td>
<td align="right">-0.54</td>
<td align="right">-0.55</td>
<td>1.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">229.38</td>
<td align="right">-0.65</td>
<td align="right">-0.29</td>
<td>415</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">77.18</td>
<td align="right">-0.04</td>
<td align="right">-0.06</td>
<td>1.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">88.72</td>
<td align="right">-0.02</td>
<td align="right">-0.03</td>
<td>653</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For January 23, 2025

Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) reported quarterly adjusted earnings of $0.31 per share which beat the analyst consensus estimate of $0.22 by 40.91 percent. This is a 14.81 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $5.72 billion which missed the analyst consensus estimate of $5.99 billion by 4.51 percent. This is a 3.13 percent decrease over sales of $5.91 billion the same period last year.

Freeport-McMoRan Q4 Adj $0.31 Beats $0.22 Estimate, Sales $5.72B Miss $5.99B Estimate

Barclays analyst Alex Scott maintains Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) with a Equal-Weight and raises the price target from $127 to $128.

Barclays Maintains Equal-Weight on Prudential Financial, Raises Price Target to $128

LiveOne Surpasses 600,000 Tesla Users, Says 275,000 Are Ad-Supported Users

Barclays analyst Lauren Lieberman maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Equal-Weight and raises the price target from $155 to $159.

Barclays Maintains Equal-Weight on Procter & Gamble, Raises Price Target to $159

NOVAGOLD RESOURCES INC. ("NOVAGOLD" or "the Company") ((NYSE American, TSX:<a href="https://www.benzinga.com/stock/NG#TSX">NG</a>) today filed its 2024 fiscal year-end report and provided an update on its Tier One1 gold development project, Donlin Gold, which NOVAGOLD owns equally with Barrick Gold Corporation ("Barrick").
Details of the financial results for the year ended November 30, 2024, are presented in the consolidated financial statements and annual report on Form 10-K filed on January 23, 2025 which is available on the Company's website at <a href="http://www.novagold.com/">www.novagold.com</a>, on SEDAR+ at <a href="http://www.sedarplus.ca/">www.sedarplus.ca</a>, and on EDGAR at <a href="http://www.sec.gov/">www.sec.gov</a>. All amounts are in U.S. dollars unless otherwise stated.
As detailed in the above filings, NOVAGOLD held a strong treasury of approximately $101 million in cash and term deposits as of November 30, 2024, and reported net annual cash expenditures of $24.5 million — including $12.4 million to fund NOVAGOLD's share of the Donlin Gold project and $17.7 million in corporate general and administrative costs, below its 2024 expenditure guidance of $31.2 million. As NOVAGOLD is a development-stage company with no production, the Company reported earnings of ($45.6) million and earnings per share of ($0.14) for the 2024 fiscal year, reflecting expenditures in line with budget.

Comments

Anteris Technologies

Anteris Technologies (AVR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga